Nifty
Sensex
:
:
24502.15
80519.34
186.20 (0.77%)
622.00 (0.78%)

Pharmaceuticals & Drugs - Global

Rating :
59/99

BSE: 533573 | NSE: APLLTD

989.05
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  965.00
  •  1018.00
  •  965.00
  •  961.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  528915
  •  5271.15
  •  1094.00
  •  641.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 19,353.61
  • 31.43
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 19,657.49
  • 1.12%
  • 4.02

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.61%
  • 0.30%
  • 7.48%
  • FII
  • DII
  • Others
  • 4.32%
  • 15.03%
  • 3.26%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.72
  • 6.22
  • 5.49

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.97
  • -5.14
  • 1.30

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.10
  • -5.77
  • 5.74

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.67
  • 19.89
  • 29.33

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.04
  • 3.40
  • 2.96

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.06
  • 15.15
  • 16.58

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
1,516.98
1,406.45
7.86%
1,630.57
1,509.02
8.05%
1,594.93
1,475.01
8.13%
1,486.15
1,262.14
17.75%
Expenses
1,256.92
1,194.23
5.25%
1,364.21
1,260.26
8.25%
1,386.69
1,242.27
11.63%
1,287.46
1,247.49
3.20%
EBITDA
260.06
212.22
22.54%
266.36
248.76
7.08%
208.24
232.74
-10.53%
198.69
14.65
1,256.25%
EBIDTM
17.14%
15.09%
16.34%
16.48%
13.06%
-4.88%
13.37%
1.16%
Other Income
3.59
0.89
303.37%
2.89
0.44
556.82%
10.15
0.33
2,975.76%
11.67
1.08
980.56%
Interest
10.94
14.37
-23.87%
15.17
14.60
3.90%
15.69
12.41
26.43%
14.39
8.79
63.71%
Depreciation
69.48
74.12
-6.26%
69.45
66.51
4.42%
67.56
67.70
-0.21%
66.18
67.10
-1.37%
PBT
183.23
124.62
47.03%
184.63
168.09
9.84%
135.14
152.96
-11.65%
129.79
-60.16
-
Tax
4.63
-36.43
-
4.13
32.57
-87.32%
-1.93
17.96
-
9.16
-1.50
-
PAT
178.60
161.05
10.90%
180.50
135.52
33.19%
137.07
135.00
1.53%
120.63
-58.66
-
PATM
11.77%
11.45%
11.07%
8.98%
8.59%
-10.84%
8.12%
-4.65%
EPS
9.07
7.76
16.88%
9.18
6.20
48.06%
6.95
-0.96
-
6.14
-3.35
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
-
6,228.62
5,652.62
5,305.78
5,393.14
4,605.76
3,934.69
3,130.81
3,134.61
3,165.99
2,056.13
Net Sales Growth
-
10.19%
6.54%
-1.62%
17.10%
17.06%
25.68%
-0.12%
-0.99%
53.98%
 
Cost Of Goods Sold
-
1,715.08
1,708.82
1,446.43
1,257.35
1,039.38
992.71
886.19
887.57
823.95
639.85
Gross Profit
-
4,513.54
3,943.80
3,859.35
4,135.79
3,566.38
2,941.98
2,244.62
2,247.04
2,342.04
1,416.28
GP Margin
-
72.46%
69.77%
72.74%
76.69%
77.43%
74.77%
71.69%
71.68%
73.97%
68.88%
Total Expenditure
-
5,296.00
4,944.56
4,431.64
3,913.05
3,391.69
3,078.87
2,515.55
2,519.90
2,160.88
1,660.92
Power & Fuel Cost
-
173.37
151.54
120.84
118.72
102.40
88.86
70.35
64.20
58.89
43.31
% Of Sales
-
2.78%
2.68%
2.28%
2.20%
2.22%
2.26%
2.25%
2.05%
1.86%
2.11%
Employee Cost
-
1,446.29
1,169.13
1,133.00
1,051.17
906.44
746.69
622.81
558.83
472.85
306.76
% Of Sales
-
23.22%
20.68%
21.35%
19.49%
19.68%
18.98%
19.89%
17.83%
14.94%
14.92%
Manufacturing Exp.
-
387.71
409.37
379.15
372.18
368.41
269.25
244.53
289.79
271.51
263.38
% Of Sales
-
6.22%
7.24%
7.15%
6.90%
8.00%
6.84%
7.81%
9.24%
8.58%
12.81%
General & Admin Exp.
-
525.84
492.64
413.90
391.24
339.82
340.56
283.43
299.79
233.28
145.68
% Of Sales
-
8.44%
8.72%
7.80%
7.25%
7.38%
8.66%
9.05%
9.56%
7.37%
7.09%
Selling & Distn. Exp.
-
996.88
952.30
890.38
687.41
531.19
590.28
380.21
393.14
274.14
244.69
% Of Sales
-
16.00%
16.85%
16.78%
12.75%
11.53%
15.00%
12.14%
12.54%
8.66%
11.90%
Miscellaneous Exp.
-
50.83
60.76
47.94
34.98
104.05
50.52
28.03
26.58
26.26
244.69
% Of Sales
-
0.82%
1.07%
0.90%
0.65%
2.26%
1.28%
0.90%
0.85%
0.83%
0.84%
EBITDA
-
932.62
708.06
874.14
1,480.09
1,214.07
855.82
615.26
614.71
1,005.11
395.21
EBITDA Margin
-
14.97%
12.53%
16.48%
27.44%
26.36%
21.75%
19.65%
19.61%
31.75%
19.22%
Other Income
-
29.04
3.04
50.49
87.48
13.88
27.14
34.87
2.58
8.83
12.09
Interest
-
56.19
50.17
17.73
16.02
27.16
18.41
3.40
5.23
5.43
3.81
Depreciation
-
272.67
275.43
286.78
183.47
157.32
115.23
105.46
82.97
72.21
44.41
PBT
-
632.80
385.50
620.12
1,368.08
1,043.47
749.32
541.27
529.09
936.30
359.07
Tax
-
16.01
12.60
104.46
253.32
199.18
156.75
120.36
122.19
216.12
76.35
Tax Rate
-
2.53%
3.27%
16.85%
18.52%
19.92%
20.92%
22.24%
23.09%
23.08%
21.26%
PAT
-
615.82
341.99
520.94
1,114.76
828.76
593.65
420.72
406.99
720.18
282.72
PAT before Minority Interest
-
615.82
341.99
520.94
1,114.76
800.64
592.57
420.91
406.90
720.18
282.72
Minority Interest
-
0.00
0.00
0.00
0.00
28.12
1.08
-0.19
0.09
0.00
0.00
PAT Margin
-
9.89%
6.05%
9.82%
20.67%
17.99%
15.09%
13.44%
12.98%
22.75%
13.75%
PAT Growth
-
80.07%
-34.35%
-53.27%
34.51%
39.60%
41.10%
3.37%
-43.49%
154.73%
 
EPS
-
31.32
17.40
26.50
56.70
42.15
30.20
21.40
20.70
36.63
14.38

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
4,818.20
4,370.47
5,237.54
5,066.98
3,219.42
2,718.83
2,220.14
1,902.33
1,597.36
884.64
Share Capital
39.31
39.31
39.31
39.31
37.70
37.70
37.70
37.70
37.70
37.70
Total Reserves
4,778.89
4,331.16
5,198.23
5,027.67
3,181.72
2,681.13
2,182.44
1,864.63
1,559.66
846.94
Non-Current Liabilities
2.75
52.42
162.07
361.16
1,046.98
570.06
576.20
94.15
84.02
72.44
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
18.80
Unsecured Loans
0.00
0.00
0.00
199.89
886.99
499.30
500.00
0.00
0.00
0.00
Long Term Provisions
109.51
106.20
95.82
85.52
74.51
52.03
40.76
57.22
28.23
9.36
Current Liabilities
1,520.28
1,640.80
1,830.59
1,533.26
1,751.61
1,663.65
1,267.18
813.96
944.19
684.09
Trade Payables
735.64
679.81
706.39
668.78
625.93
644.34
759.32
500.73
565.65
324.94
Other Current Liabilities
223.66
251.19
516.51
557.92
226.98
380.19
142.89
81.28
51.80
44.56
Short Term Borrowings
430.45
635.87
430.00
0.02
860.50
429.13
207.78
88.51
113.71
219.70
Short Term Provisions
130.53
73.93
177.69
306.54
38.20
209.99
157.19
143.44
213.03
94.88
Total Liabilities
6,341.23
6,063.69
7,230.20
6,961.40
5,989.05
4,951.75
4,063.83
2,810.55
2,625.57
1,641.17
Net Block
2,546.71
2,398.45
1,797.85
1,788.42
1,551.84
1,158.45
993.38
799.40
708.09
546.87
Gross Block
3,875.21
3,467.50
2,840.33
2,545.39
2,132.41
1,522.57
1,242.47
950.09
1,093.63
861.06
Accumulated Depreciation
1,328.50
1,069.05
1,042.48
756.97
580.57
364.12
249.09
150.69
385.54
314.19
Non Current Assets
3,197.39
3,149.80
4,255.37
4,056.96
3,526.30
2,820.02
2,116.31
1,316.80
917.30
750.43
Capital Work in Progress
524.36
601.28
2,304.24
2,182.53
1,846.18
1,551.23
1,010.15
396.28
92.52
83.14
Non Current Investment
93.02
96.33
118.40
49.31
17.62
48.76
41.64
49.88
53.43
2.26
Long Term Loans & Adv.
33.30
53.74
34.88
36.70
110.66
61.58
71.14
71.24
29.96
118.15
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
33.30
0.00
Current Assets
3,143.84
2,913.89
2,974.83
2,904.44
2,462.75
2,131.73
1,947.52
1,493.75
1,708.27
890.74
Current Investments
0.00
0.00
0.00
186.97
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
1,643.54
1,475.27
1,609.70
1,486.15
1,187.54
967.27
733.93
632.75
569.79
382.77
Sundry Debtors
1,024.84
1,046.41
807.13
348.60
864.75
488.92
526.34
338.82
350.48
361.17
Cash & Bank
126.57
82.27
69.43
105.84
80.75
205.62
89.92
159.60
450.83
26.83
Other Current Assets
348.89
55.32
51.65
78.67
329.71
469.92
597.33
362.58
337.17
119.98
Short Term Loans & Adv.
289.03
254.62
436.92
698.21
301.61
451.71
569.84
355.02
330.08
119.98
Net Current Assets
1,623.56
1,273.09
1,144.24
1,371.18
711.14
468.08
680.34
679.79
764.08
206.65
Total Assets
6,341.23
6,063.69
7,230.20
6,961.40
5,989.05
4,951.75
4,063.83
2,810.55
2,625.57
1,641.17

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
803.21
723.94
552.35
1,463.38
449.15
811.97
312.42
328.55
947.65
171.76
PBT
631.83
354.59
625.39
1,368.08
999.82
749.32
541.27
529.09
936.31
359.07
Adjustment
286.86
487.61
417.75
102.42
278.28
117.57
87.12
83.06
69.45
44.61
Changes in Working Capital
-95.63
-57.56
-367.36
238.30
-592.84
111.56
-180.85
-165.64
138.90
-162.50
Cash after chg. in Working capital
823.06
784.64
675.78
1,708.80
685.26
978.45
447.54
446.51
1,144.66
241.18
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-19.85
-60.70
-123.43
-245.42
-236.11
-166.48
-135.12
-117.96
-197.01
-69.42
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-320.61
-447.59
-371.97
-838.80
-731.63
-755.60
-884.38
-485.91
-306.80
-255.61
Net Fixed Assets
-340.94
994.77
-402.51
-1,303.18
-789.71
-638.70
-606.86
-121.60
-288.80
-200.26
Net Investments
2.59
-9.91
123.73
490.16
-326.86
-207.50
-195.85
-65.58
-4.13
0.00
Others
17.74
-1,432.45
-93.19
-25.78
384.94
90.60
-81.67
-298.73
-13.87
-55.35
Cash from Financing Activity
-437.87
-261.96
-217.35
-597.42
154.85
59.03
502.63
-128.88
-224.30
86.72
Net Cash Inflow / Outflow
44.73
14.39
-36.97
27.16
-127.63
115.40
-69.33
-286.24
416.55
2.86
Opening Cash & Equivalents
75.48
61.09
98.06
71.83
199.06
83.74
153.07
439.32
22.77
23.96
Closing Cash & Equivalent
120.21
75.48
61.09
98.06
71.84
199.07
83.74
153.08
439.32
26.83

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
245.14
222.36
266.47
257.80
170.79
144.24
117.78
100.92
84.74
46.93
ROA
9.93%
5.15%
7.34%
17.22%
14.64%
13.15%
12.25%
14.97%
33.76%
18.76%
ROE
13.40%
7.12%
10.11%
26.91%
26.97%
24.00%
20.42%
23.25%
58.03%
36.24%
ROCE
13.42%
7.44%
11.25%
26.28%
23.30%
22.66%
22.15%
28.87%
65.87%
37.54%
Fixed Asset Turnover
1.70
1.79
1.97
2.31
2.52
2.85
2.86
3.07
3.24
2.71
Receivable days
60.69
59.84
39.75
41.06
53.64
47.09
50.43
40.13
41.02
55.91
Inventory Days
91.38
99.60
106.49
90.48
85.38
78.91
79.67
70.01
54.91
61.11
Payable days
150.62
148.04
173.51
187.92
69.87
88.23
98.47
84.03
80.04
69.83
Cash Conversion Cycle
1.45
11.40
-27.27
-56.39
69.15
37.76
31.63
26.12
15.89
47.19
Total Debt/Equity
0.09
0.15
0.12
0.10
0.54
0.42
0.32
0.05
0.07
0.30
Interest Cover
12.24
8.07
36.27
86.40
37.81
41.70
160.20
102.16
173.43
95.30

News Update:


  • Alembic Pharmaceuticals gets USFDA’s tentative nod for Selexipag for Injection
    12th Jul 2024, 17:46 PM

    Alembic has a cumulative total of 208 ANDA approvals from USFDA

    Read More
  • Alembic Pharma gets USFDA’s final approval for Bromfenac Ophthalmic Solution
    9th Jul 2024, 14:09 PM

    The company has a cumulative total of 207 ANDA approvals (180 final approvals and 27 tentative approvals) from USFDA

    Read More
  • Alembic Pharma gets USFDA’s tentative approval for Ivosidenib Tablets
    4th Jul 2024, 12:44 PM

    The company has a cumulative total of 207 ANDA approvals (179 final approvals and 28 tentative approvals) from USFDA

    Read More
  • Alembic Pharma gets USFDA’s final nod for Doxycycline Capsules
    28th Jun 2024, 11:42 AM

    The company has a cumulative total of 205 ANDA approvals (179 final approvals and 26 tentative approvals) from USFDA

    Read More
  • Alembic Pharmaceuticals gets USFDA’s nod for Dabigatran Etexilate Capsules
    18th Jun 2024, 14:42 PM

    The company has a cumulative total of 205 ANDA approvals (178 final approvals and 27 tentative approvals) from USFDA

    Read More
  • Alembic Pharma gets USFDA’s final nod for Icatibant Injection
    17th Jun 2024, 14:05 PM

    The company has a cumulative total of 205 ANDA approvals (177 final approvals and 28 tentative approvals) from USFDA

    Read More
  • Alembic Pharma gets USFDA’s final nod for Sacubitril and Valsartan tablets
    30th May 2024, 14:13 PM

    The company has a cumulative total of 202 ANDA approvals (174 final approvals and 28 tentative approvals) from USFDA

    Read More
  • Alembic Pharmaceuticals reports 17% rise in Q4 consolidated net profit
    10th May 2024, 14:58 PM

    Total consolidated income of the company increased by 8.05% at Rs 1,520.57 crore for Q4FY24

    Read More
  • Alembic Pharma - Quarterly Results
    9th May 2024, 14:17 PM

    Read More
  • Alembic Pharmaceuticals gets EIR for oncology formulation facility (F-2) at Panelav
    6th May 2024, 09:48 AM

    The company has received an EIR from USFDA

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.